Takeda’s Successor Drug to Actos Fails to Win Approval

Takeda Pharmaceutical Co., Asia’s biggest drugmaker, failed to win clearance to sell its new diabetes treatment in the U.S., with regulators asking for more information on the use of the medicine in other countries.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.